Form DEFR14A - Revised definitive proxy soliciting materials:
SEC Accession No. 0000950170-25-057632
Filing Date
2025-04-24
Accepted
2025-04-23 20:46:51
Documents
24

Document Format Files

Seq Description Document Type Size
1 DEFR14A tngx-20250424.htm   iXBRL DEFR14A 1740518
2 GRAPHIC img161881705_0.jpg GRAPHIC 18128
3 GRAPHIC img161881705_1.jpg GRAPHIC 12976
4 GRAPHIC img161881705_2.jpg GRAPHIC 18128
5 GRAPHIC img161881705_3.jpg GRAPHIC 10618
6 GRAPHIC img161881705_4.jpg GRAPHIC 18128
7 GRAPHIC img161881705_5.jpg GRAPHIC 69377
8 GRAPHIC img161881705_6.jpg GRAPHIC 48235
9 GRAPHIC img161881705_7.jpg GRAPHIC 469376
10 GRAPHIC img161881705_8.jpg GRAPHIC 182495
  Complete submission text file 0000950170-25-057632.txt   5217426

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tngx-20250424.xsd EX-101.SCH 18800
27 EXTRACTED XBRL INSTANCE DOCUMENT tngx-20250424_htm.xml XML 587381
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFR14A | Act: 34 | File No.: 001-39485 | Film No.: 25863253
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)